Exclusive: FDA probing death of Aduhelm patient as Biogen's Alzheimer's drug continues to stir controversy

John Carroll

Editor & Founder

Zachary Brennan

Senior Editor

The FDA tells Endpoints News today that it’s aware of the death of a patient taking Biogen’s controversial Alzheimer’s drug Aduhelm (aducanumab) and is “actively …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: FDA probing death of Aduhelm patient as Biogen's Alzheimer's drug continues to stir controversy

John Carroll

Editor & Founder

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Trump names Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, Surgeon General picks

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

FDA vaccine chief Peter Marks pledges to stay as long as he's welcome

Patient dies in Neurogene's Rett syndrome study

Are programs with compounded GLP-1s safe for your population?

Ex­clu­sive: FDA prob­ing death of Aduhelm pa­tient as Bio­gen's Alzheimer's drug con­tin­ues to stir con­tro­ver­sy

Editor & Founder

Senior Editor

Sign up to read this article for free.

Exclusive: FDA probing death of Aduhelm patient as Biogen's Alzheimer's drug continues to stir controversy